Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

Anne Wojcicki won a bid to purchase the genetic testing platform through her nonprofit TTAM Research Institute. The $305M deal was part of a bankruptcy auction, beating out offers from Regeneron ...

UnitedHealth Group ( UNH -1.61%) was the worst-performing stock in the S&P 500 last month. It plunged 26.6% to 52-week lows of $248.88 per share on May 15 after CEO Andrew Witty abruptly resigned and ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Me, which became a household name for its genetic testing services, is set to emerge from bankruptcy as a nonprofit.

WilmerHale shouldn’t be permitted to represent a law professor making privacy-related recommendations about the sale of ...

Anne Wojcicki's nonprofit will acquire substantially all of 23andMe's assets for $305 million, the company announced Friday. 23andMe filed for Chapter 11 bankruptcy protection in March. Last month, ...